Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Cordis wins FDA approval for sirolimus-eluting balloon

22 September 2026 · By · Wire by Fusion42

Published

22 September 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at medtechdive.com →

◆ Verified

Fusion42 · 22 September 2026 · Fusion42 review

Cordis has received FDA approval for its sirolimus-eluting balloon, providing a new option for physicians alongside uncoated balloons and Boston Scientific’s paclitaxel-coated device.

This Wire brief sits within Fusion42's coverage of Medtech, and 3 sources have reported it between 22 Sep 2026 and 28 Sep 2026.

◆ ◆ The Wire takeaway

FDA approval for a new sirolimus-eluting balloon opens a market entry point for medical device founders focused on vascular interventions; you can now position your innovation against established drug-coated balloons.

◆ Coverage

3 sources · first reported 22 Sep 2026 · latest 28 Sep 2026

◆ Related on Wire

◆ Topics

Medtechfda-approvalmedtechcardiacdevice-innovationsirolimus